This is a summary of the European public assessment report (EPAR) for Axura. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Axura.
Therapeutic Indication
### Therapeutic indication Treatment of patients with moderate to severe Alzheimer's disease.
Therapeutic Area (MeSH)
ATC Code
N06DX01
ATC Item
memantine
Pharmacotherapeutic Group
Other anti-dementia drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| memantine hydrochloride | N/A | 美金刚 |
EMA Name
Axura
Medicine Name
Axura
Aliases
N/ANo risk management plan link.
